Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Health & Fitness
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
Loading...
0:00 / 0:00
Podjoint Logo
US
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/93/46/6e/93466e84-fde2-bda5-d95f-c965e127fbdc/mza_16279354008947390636.jpg/600x600bb.jpg
Cures & Capital
Martin Slezak and Simon Birksø
15 episodes
2 weeks ago
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development. We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adapti...
Show more...
Business
RSS
All content for Cures & Capital is the property of Martin Slezak and Simon Birksø and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development. We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adapti...
Show more...
Business
Episodes (15/15)
Cures & Capital
Scott Berry on Rethinking Clinical Trials: Bayesian Design, Adaptivity, and Smarter Decisions
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development. We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adapti...
Show more...
2 weeks ago
1 hour 19 minutes

Cures & Capital
Deborah Dunsire on leading in today’s biopharma landscape
In this episode, we talk to Deborah Dunsire, board chair at Neurvati Neurosciences, multiple times board member, and a former CEO of Lundbeck. With more than 3 decades of experience, Deborah has navigated organizations of every size through change, uncertainty, and opportunity. We explore what it takes to lead in today’s biopharma landscape - from rolling up your sleeves in biotech to streamlining decisions in big pharma, and from balancing short-term survival in a capital-constrained enviro...
Show more...
2 months ago
1 hour 4 minutes

Cures & Capital
Dr. Andrée Bates on AI that works: from pilot chaos to real impact
In this episode, we talk to Dr. Andrée Bates, founder and CEO of Eularis, a company helping clients accelerate pharma business results through Artificial Intelligence. We explore how the biopharma industry can move beyond scattered pilots toward strategic, enterprise-wide AI integration. Drawing on decades at the forefront of AI in pharma, Dr. Bates shares practical insights on building the foundations for long-term value creation and turning AI into a true competitive advantage. We also di...
Show more...
4 months ago
1 hour 18 minutes

Cures & Capital
Leon 'Jun' Tang: Inside the Rise of China's Biotech Industry
How did China become a serious force in global biotech in just over a decade? This is the insider story of China's biotech boom! Dr. Leon 'Jun' Tang, founding partner of InScienceWeTrust BioAdvisory, joins Cures & Capital to unpack the rise of Chinese biopharma. From talent migration and government planning to innovation in ADCs and the challenges of commercialization. Chapters 00:00 - Introduction & Leon’s global background 01:13 - Guest introduction - Leon 'Jun' Tang 05:35 - Impac...
Show more...
4 months ago
1 hour 18 minutes

Cures & Capital
Jason O'Neill on cracking the code to successful drug launches - Part 2
In this episode, we talk to Jason O’Neill, former CEO of Dendreon and Iridium Therapeutics, and author of The Secrets of Successful Drug Launches. This conversation is a practical guide to new drug launches, packed with Jason's hard-won insights. We explore why so many launches fail, the psychology behind adoption resistance, what meaningful relative advantage really means, how to plan for a successful launch, and when you actually need to start thinking about commercialization. This episod...
Show more...
5 months ago
52 minutes

Cures & Capital
Jason O'Neill on cracking the code to successful drug launches - Part 1
In this episode, we talk to Jason O’Neill, former CEO of Dendreon and Iridium Therapeutics, and author of The Secrets of Successful Drug Launches. This conversation is a practical guide to new drug launches, packed with Jason's hard-won insights. We explore why so many launches fail, the psychology behind adoption resistance, what meaningful relative advantage really means, how to plan for a successful launch, and when you actually need to start thinking about commercialization. This episod...
Show more...
5 months ago
42 minutes

Cures & Capital
Episode 9 - Reflections and Takeaways
Over the past few months, we’ve had the chance to speak with some of the sharpest minds in the industry—thinkers and practitioners who have shaped how we understand drug innovation, R&D productivity, portfolio strategy, and other critical topics. In this episode, we bring together the major insights and lessons, highlighting patterns that emerged across the different conversations. We also spotlight the unique takeaways from each guest to help ensure these key learnings really stick. Wh...
Show more...
5 months ago
33 minutes

Cures & Capital
Aaron Schacht on the pharmaceutical industry's grand challenge and managing R&D at scale
In this episode, we talk to Aaron Schact, the CEO and Board Director at BiomEdit and former R&D leader at Eli Lilly and Elanco. We discuss how to improve biopharma's R&D productivity and the industry's "grand challenge", why R&D productivity is the mental model for managing R&D at scale, practical advice on how to approach and work with R&D productivity, and much more! If you want to connect with us - we would love to hear from you: Linkedin: https://www.linkedin.c...
Show more...
6 months ago
53 minutes

Cures & Capital
Matthias Krings on crafting winning biopharma strategies and smart decisions
In this episode, our guest is Dr. Matthias Krings - a senior partner at Catenion, a biopharma strategy consulting firm. Matthias is a seasoned veteran in biopharma strategy. In this conversation, he shares his playbook for achieving success as a biopharma company. As critical pillars for biopharma success, we dive into strategy processes, decision-making, and effective R&D risk management. If you want to connect with us - we would love to hear from you: LinkedIn: https://www.linkedin.com/...
Show more...
6 months ago
49 minutes

Cures & Capital
Stephan Christgau on applying the VC mindset in biotech & pharma
How do venture capitalists think? And how do they define and create value in the life science industry? In this episode, we talk to Stephan Christgau, founding partner of Eir Ventures, about the VC mindset, investment decision-making and portfolio strategy. We dive into how VCs assess risk, balance high-stakes opportunities, and what could pharma and biotech companies learn from the VC way of doing things. If you want to connect with us - we would love to hear from you: Linkedin: https://ww...
Show more...
7 months ago
1 hour 3 minutes

Cures & Capital
Murray Aitken's guide to biotech & pharma leaders: Navigating great uncertainty and complexity
In this episode, we sit down with Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, to discuss the trends shaping the life sciences industry in 2025 and beyond. How do we navigate the life sciences industry in times of great uncertainty? Murray has observed the life sciences industry for decades and lays out his balanced perspective of the state of the industry and the underlying uncertainties, challenges and opportunities. This episode is a must-watch for anyon...
Show more...
8 months ago
1 hour

Cures & Capital
Mike Rea on why pharma struggles with innovation - and how to fix it
In this episode, Mike Rea - CEO, IDEA Pharma - takes us on a journey through innovation and value creation in pharma. It is not all roses! He shares his candid views on what the pharmaceutical industry needs to do better to be less confused about innovation. Mike Rea also explains the importance of getting the definition of innovation right in drug development. Early commercial involvement in drug R&D is another key pillar in his drug innovation philosophy. We also get to discuss organiza...
Show more...
8 months ago
1 hour 8 minutes

Cures & Capital
Kelvin Stott on what it takes to fix pharma's broken business model
In this episode, Kelvin Stott talks about why might be pharma's business model broken and how can it be fixed, the declining ROI on drug R&D, better R&D portfolio decision making, raising the bar in pharma/biotech innovation and more. Kelvin Stott has over 20 years of diverse leadership experience in pharma R&D strategy and operations, drug discovery and development, portfolio management, strategy consulting, biotech start-ups and venture capital. Currently, he is the Found...
Show more...
9 months ago
1 hour

Cures & Capital
Jack Scannell on drug R&D decision-making: The value of getting it right
In this episode, Dr. Jack Scannell delves into topics such as R&D productivity, decision-making, model validity, and more. If you're looking to deepen your understanding of these areas, there's no better guide than Jack. Jack brings a deep and holistic understanding of the biotech and pharma industry, having held a variety of roles—including being a neuroscientist, strategy consultant, investment analyst, and now the CEO of Etheros Pharmaceuticals. Chapters: 00:00 Intro 02:08 Guest int...
Show more...
9 months ago
1 hour 18 minutes

Cures & Capital
Cures & Capital: Trailer Episode
EPISODE 1 - Cures & Capital: Trailer Episode In this episode, we introduce the scope and mission of the podcast. Our focus with Cures & Capital is the intersection between drug R&D and finance. Hosts: Martin Slezak & Simon Birksø. Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinion...
Show more...
9 months ago
3 minutes

Cures & Capital
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development. We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adapti...